531 related articles for article (PubMed ID: 18511823)
1. Working together to enhance the efficiency of medical product development.
Sanhai WR
J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
[No Abstract] [Full Text] [Related]
2. Looking for solid ground along the Critical Path.
Ratner M
Nat Biotechnol; 2006 Aug; 24(8):885-7. PubMed ID: 16900118
[No Abstract] [Full Text] [Related]
3. Vioxx, radiology, and the Food and Drug Administration.
Pentecost MJ
J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
[No Abstract] [Full Text] [Related]
4. Microarray data--the US FDA, industry and academia.
Hackett JL; Lesko LJ
Nat Biotechnol; 2003 Jul; 21(7):742-3. PubMed ID: 12833089
[No Abstract] [Full Text] [Related]
5. Facilitating product development.
Lanser EG
Healthc Exec; 2001; 16(3):62-3. PubMed ID: 11372237
[No Abstract] [Full Text] [Related]
6. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
7. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
8. Is FDA's medical device evaluation process overly complaisant to industry?
Margolis RE
Healthspan; 1992; 9(7):19-20. PubMed ID: 10121440
[No Abstract] [Full Text] [Related]
9. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
Friedman MA
Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
[No Abstract] [Full Text] [Related]
10. Medical device regulation in the United States and the European Union: a comparative study.
Chai JY
Food Drug Law J; 2000; 55(1):57-80. PubMed ID: 12296349
[No Abstract] [Full Text] [Related]
11. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
12. Remarks by the Commissioner of Food and Drugs.
Kessler DA
Food Drug Law J; 1996; 51(2):207-15. PubMed ID: 11817358
[No Abstract] [Full Text] [Related]
13. Is the Food and Drug Administration safe and effective?
Philipson TJ; Sun E
J Econ Perspect; 2008; 22(1):85-102. PubMed ID: 19728421
[No Abstract] [Full Text] [Related]
14. Memorandum of understanding between the Food and Drug Administration and the Defense Alliance for Advanced Medical Terminology--FDA. Notice.
Fed Regist; 1998 Jul; 63(129):36700-6. PubMed ID: 10181056
[TBL] [Abstract][Full Text] [Related]
15. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
16. Case Study for Lean Management in the Public Sector: Improving Combination Product Review at the Food & Drug Administration.
Rappel MJ; Hunter NL; Alexandrow AI; Hair KO; Sherman RE; Califf RM
Clin Transl Sci; 2017 May; 10(3):124-127. PubMed ID: 28079301
[No Abstract] [Full Text] [Related]
17. Devising a new approach. Proposed changes to device law aim to boost funding, streamline product review.
Rhea S
Mod Healthc; 2007 May; 37(22):30-1. PubMed ID: 17608125
[No Abstract] [Full Text] [Related]
18. Teaching the elephant to dance: privatizing the FDA review process.
Price EC
Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
[No Abstract] [Full Text] [Related]
19. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
20. Update on the Center for Devices and Radiological Health.
Jacobson ED
Food Drug Law J; 2000; 55(2):185-91. PubMed ID: 12269363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
